Screener
Arcutis Biotherapeutics, Inc. ARQT Total Operating Expenses
Discontinued — last reported Q3 '23
Total Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by Arcutis Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Arcutis Biotherapeutics, Inc.’s 10-Q, filed November 3, 2023.
- Filed
- Nov 3, 2023, 7:36 AM EDT
- Fiscal quarter
- Q3 FY2023
- Calendar quarter
- Q3 2023
- Accession
- 0001787306-23-000124
| Line item | Three Months Ended September 30, 2023 | Three Months Ended September 30, 2022 | Nine Months Ended September 30, 2023 | Nine Months Ended September 30, 2022 |
|---|---|---|---|---|
| Cost of sales | 1,182 | 269 | 2,741 | 269 |
| Research and development | 26,236 | 69,731 | 86,800 | 148,558 |
| Selling, general, and administrative | 47,595 | 35,473 | 136,471 | 85,101 |
| Total operating expenses | 75,013 | 105,473 | 226,012 | 233,928 |
| Loss from operations | (36,904) | (104,748) | (179,932) | (233,203) |
| Other income (expense): | ||||
| Other income, net | 2,721 | 1,938 | 9,114 | 2,501 |
| Interest expense | (7,559) | (4,899) | (21,950) | (8,737) |
Item 1. Financial Statements
FAQ
- What is Arcutis Biotherapeutics, Inc.'s total operating expenses?
- Arcutis Biotherapeutics, Inc. (ARQT) reported total operating expenses of $75.01M in Q3 2023.
- How has Arcutis Biotherapeutics, Inc.'s total operating expenses changed year-over-year?
- Arcutis Biotherapeutics, Inc.'s total operating expenses decreased by 28.9% year-over-year, from $105.47M to $75.01M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.
Ask your AI about Arcutis Biotherapeutics, Inc.'s total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude